Brief: Cytokinetics Announces Positive Topline Results From Acacia-Hcm, The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Non-Obstructive Hypertrophic Cardiomyopathy
05/05/2026 12:44
May 5 (Reuters) - Cytokinetics Inc CYTK.O: CYTOKINETICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ACACIA-HCM, THE PIVOTAL PHASE 3 CLINICAL TRIAL OF AFICAMTEN IN PATIENTS WITH NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY CYTOKINETICS INC - ACACIA-HCM MEETS DUAL PRIMARY ENDPOINTS IN KCCQ-CSS AND MAXIMAL EXERCISE PERFORMANCE AT WEEK 36 CYTOKINETICS INC - NO NEW SAFETY SIGNALS IDENTIFIED; COMPLETION RATES SIMILAR FOR AFICAMTEN AND PLACEBO Source text: ID:nGNX8tfgQ0 Further company coverage: CYTK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytokinetics, Incorporated
See all newsBrief: Cytokinetics To Announce Third Quarter Results On November 4, 2026
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Cytokinetics Announces Additional Data From Acacia-Hcm Presented At The Hfsa Annual Scientific Meeting 2026
Brief: Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech